We picked up a useful guide published by Deloitte recently - published last year but still very relevant today:
“Executing an open innovation model: co-operation is key to competition for biopharmaceutical companies”
It’s a relatively short but punchy guide to why open innovation would prove beneficial to the industry, along with a clear explanation of the model. It also discusses the key types of innovation prevalent in biopharma and usefully maps them on a scale of openness so readers can assess their own organisation’s progress.
The report further examines five key elements of innovation - network characteristics, talent, IP management, participant impacts and governance and makes suggestions for actions organisations can take to move further towards an open model.